Evenamide targets hippocampal hyperactivity, addressing positive, negative, and cognitive symptoms in TRS without typical D2 antagonist side effects.
7 Likes
Great news, I think it could be better than Cobenfy… or at least similar, but without some side effects. We will see in near future which one is better. 
1 Like
So you think it will be so good? When will be available in USA and in Europe ?
Well, I think it could be very good, but we will see…
AI said:
Evenamide does not have a commercial release date yet, as it is still in late-stage clinical trials. Following positive results from a Phase III trial, Newron Pharmaceuticals expects to file for regulatory approval in the first half of 2027 and a potential launch could occur around 2028.
- Current status: Evenamide is currently in Phase III clinical trials for treatment-resistant schizophrenia.
- Regulatory timeline: A potential filing for approval could happen in the first half of 2027 if the Phase III trial results are positive.
- Potential launch: The earliest possible commercial launch is projected for around 2028, pending successful regulatory approval.
Newron Pharmaceuticals is company from Italy so Evenamide maybe will be launched in EU before USA, but we will see in near future, for one year or two…
2 Likes
Thanks for the article. This could be very big. I wish it were in trials as a monotherapy so that it would be available outside TRS sooner.
2 Likes